熱門資訊> 正文
Vertex为糖尿病候选人授权细胞治疗技术
2024-04-23 21:12
- Vertex Pharmaceuticals (NASDAQ:VRTX) announced Tuesday an agreement with French biotech TreeFrog Therapeutics to obtain an exclusive license for the latter’s cell manufacturing technology, C-Stem, targeting VRTX’s cell therapies for type 1 diabetes.
- Under the collaboration, the duo will scale up the development of differentiated, insulin-producing pancreatic islet cells with a focus on VRTX’s T1D cell therapy portfolio.
- As part of the agreement, TreeFrog will receive $25M upfront and an equity investment from Vertex (VRTX), a U.S. biotech focused on cystic fibrosis therapies. It’s also eligible to receive up to $215M in milestone payments in connection with an initial development process.
- Payments linked to clinical, regulatory, and commercial milestones for two potential products are expected to reach $250M in addition to single-digit royalties.
More on Vertex Pharmaceuticals
- Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse
- Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
- What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences
- Vertex starts rolling FDA submission for non-opioid pain therapy
- TD Cowen says sickle cell therapies may get higher CMS payments
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
